Lilly reports positive interim data on breast cancer combo drug

April 24 (Reuters) - Eli Lilly and Co said the combination of its experimental breast cancer drug and a commonly used treatment met the main goal of a late-stage study in an interim analysis, setting the stage for a regulatory submission later this year.